Showing results (171-180 of 380) with videos related to

Sort By:
Pageof 38
Blood|January 6, 2016
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsPreetesh Jain, Hagop Kantarjian, Keyur P Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2023
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic SyndromesSung-Eun Lee, Feng Wang, Maison Grefe, et al.
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
American Journal of Hematology|January 25, 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control studyElias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, et al.
Haematologica|October 27, 2018
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemiaEvgeniya Angelova, Charlene Audette, Yelena Kovtun, et al.
American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.
Pageof 38